Ionis Pharmaceuticals (NASDAQ:IONS) received a $50.00 target price from equities research analysts at Piper Jaffray Companies in a report released on Monday. The firm currently has a “hold” rating on the stock. Piper Jaffray Companies’ price objective points to a potential downside of 2.95% from the company’s previous close.

Several other brokerages also recently issued reports on IONS. Stifel Nicolaus cut their price objective on Ionis Pharmaceuticals from $55.00 to $48.00 and set a “hold” rating for the company in a research report on Tuesday, August 7th. Zacks Investment Research downgraded Ionis Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 17th. Morgan Stanley cut their price objective on Ionis Pharmaceuticals from $51.00 to $49.00 and set an “equal weight” rating for the company in a research report on Wednesday, August 8th. ValuEngine upgraded Ionis Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, August 9th. Finally, Barclays downgraded Ionis Pharmaceuticals from an “equal weight” rating to an “underweight” rating and set a $52.00 price objective for the company. in a research report on Wednesday, June 20th. Three investment analysts have rated the stock with a sell rating, six have issued a hold rating and two have given a buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $52.33.

Shares of IONS opened at $51.52 on Monday. The company has a quick ratio of 8.34, a current ratio of 8.38 and a debt-to-equity ratio of 0.76. Ionis Pharmaceuticals has a 52-week low of $39.07 and a 52-week high of $65.51. The firm has a market capitalization of $6.75 billion, a price-to-earnings ratio of 644.00 and a beta of 2.62.

Ionis Pharmaceuticals (NASDAQ:IONS) last issued its quarterly earnings data on Tuesday, August 7th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.09) by ($0.20). Ionis Pharmaceuticals had a negative net margin of 7.20% and a negative return on equity of 1.22%. The business had revenue of $117.75 million during the quarter, compared to the consensus estimate of $128.22 million. equities research analysts forecast that Ionis Pharmaceuticals will post -0.38 earnings per share for the current year.

In other news, SVP C Frank Bennett sold 12,500 shares of the business’s stock in a transaction on Wednesday, August 8th. The stock was sold at an average price of $45.00, for a total transaction of $562,500.00. Following the completion of the sale, the senior vice president now owns 19,409 shares in the company, valued at $873,405. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, COO Brett P. Monia sold 16,493 shares of the business’s stock in a transaction on Monday, August 27th. The stock was sold at an average price of $54.00, for a total value of $890,622.00. Following the sale, the chief operating officer now owns 24,834 shares of the company’s stock, valued at approximately $1,341,036. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 29,149 shares of company stock valued at $1,460,459. 2.44% of the stock is currently owned by corporate insiders.

Hedge funds have recently added to or reduced their stakes in the company. Point72 Asia Hong Kong Ltd raised its position in shares of Ionis Pharmaceuticals by 255.8% during the first quarter. Point72 Asia Hong Kong Ltd now owns 2,498 shares of the company’s stock worth $110,000 after acquiring an additional 1,796 shares during the last quarter. Rockefeller Capital Management L.P. bought a new stake in shares of Ionis Pharmaceuticals during the second quarter worth $156,000. TLP Group LLC raised its position in shares of Ionis Pharmaceuticals by 5,220.0% during the first quarter. TLP Group LLC now owns 4,522 shares of the company’s stock worth $199,000 after acquiring an additional 4,437 shares during the last quarter. Cambridge Investment Research Advisors Inc. bought a new stake in shares of Ionis Pharmaceuticals during the second quarter worth $212,000. Finally, Mizuho Securities USA LLC bought a new stake in shares of Ionis Pharmaceuticals during the second quarter worth $263,000. Institutional investors own 85.55% of the company’s stock.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and Kynamro an oligonucleotide inhibitor for use in patients with homozygous familial hypercholesterolemia to reduce low density lipoprotein-cholesterol, apolipoprotein B, total cholesterol, and non-high density lipoprotein.

Featured Article: What is the S&P 500 Index?

Analyst Recommendations for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.